Oncology ASCO 2024 - Warner Biddle and Ibrahim Elhoussieny ASCO is always an interesting show for Kite, the Gilead Sciences subsidiary focused on cell therapy.
News Andexxa reaches the end of the line in the US AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.